One obstacle to therapeutic use of microRNAs (miRNA), which are in clinical trial for a number of diseases, are ribonucleases, whose job it is to destroy them. Researchers report that an miRNA (miR-126) protective against sepsis can be delivered effectively via a nanocarrier. Almost 67 percent of mice treated with one of the nanocarrier/miR-126 complexes were still alive at seven days vs. just 25 percent of controls.
from Top Technology News -- ScienceDaily https://www.sciencedaily.com/releases/2018/12/181203115430.htm
from Top Technology News -- ScienceDaily https://www.sciencedaily.com/releases/2018/12/181203115430.htm
Comments
Post a Comment
Thank you for your message. We are improving our services everyday.